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Objectives
To investigate prospectively the clinical utility and influence
on decision-making of Bladder EpiCheckTM, a non-invasive
urine test, in the surveillance of non-muscle-invasive bladder
cancer (NMIBC).
Materials and Methods
Urine samples from 440 patients undergoing surveillance for
NMIBC were prospectively collected at five centres and
evaluated using the Bladder EpiCheck test (NCT02647112). A
multivariable nomogram and decision-curve analysis (DCA)
were used to evaluate the impact of Bladder EpiCheck on
decision-making when used in routine clinical practice. The
test was designed to exclude recurrent disease.
Results
Data from 357 patients were available for analysis. The test
had a specificity of 88% (95% confidence interval [CI] 84–
91), a negative predictive value (NPV) of 94.4% (95% CI
91–97) for the detection of any cancer and an NPV of
99.3% for the detection of high-grade cancer. In
multivariable analysis, positive Bladder EpiCheck results
were independently associated with any and high-grade
disease recurrence (odds ratio [OR] 18.1, 95% CI 8.7–40.2;
P < 0.001 and OR 78.3, 95% CI 19.2–547; P < 0.001). The
addition of Bladder EpiCheck to standard variables
improved its predictive ability for any and high-grade
disease recurrence by a difference of 16% and 22%,
respectively (area under the curve 85.9% and 96.1% for any
and high-grade cancer, respectively). DCA showed an
improvement in the net benefit relative to cystoscopy over
a large threshold of probability, resulting in a significant
reduction in unnecessary investigations. These results were
similar in subgroups assessing the impact of specific clinical
features.
Conclusions
Bladder EpiCheck is a robust high-performing diagnostic test
in patients with NMIBC undergoing surveillance that can
potentially reduce the number of unnecessary investigations.
Keywords
non-muscle-invasive, urinary biomarker, prediction,
surveillance, #BladderCancer, #blcsm
Introduction
Non-muscle invasive bladder cancer (NMIBC) is a disease
with recurrence rates up to 60% within the first year of
diagnosis [1]. Most patients will experience numerous
recurrences in their life while some experience disease
progression, making NMIBC a dangerous chronic disease
with many events, leading to substantial burden on patients
and healthcare systems. Surveillance of NMIBC to allow early
identification of recurrence and progression has a high socio-
economic impact, making NMIBC one of the costliest cancers
per patient [2]. Moreover, the invasiveness of cystoscopy is
associated with morbidity and reduced compliance over time
[3,4]. Urinary cytology has a high specificity for high-grade
tumours but is limited by low sensitivity and variable
performance across centres, in addition to a poor accuracy
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Trial
for low-grade tumours [3,4]. Efforts have therefore focused
on the development of non-invasive urine-based molecular
tests. While some are approved by the US Food and Drug
Administration and European Medicines Agency, none are
widely used [5–8]. Indeed, most of these tests focus on
single markers and do not consider the high mutation load
and heterogeneity of bladder cancer (BCa), resulting in
limited improvement in diagnostic performance, if any at
all, compared with urine cytology and cystoscopy, and
generating additional cost without improvement of clinical
care [9–13].
Bladder EpiCheckTM is a new promising urine-based test
which includes a panel of 15 DNA methylation patterns for
the identification of recurrent BCa. A recent multicentre
biomarker phase III trial showed that Bladder EpiCheck has a
sensitivity of 91.7% in non-Ta low-grade recurrences and
specificity of 88% for detecting BCa recurrence in patients
undergoing surveillance for NMIBC [14].
In the present paper, we report a secondary, independent
analysis, focusing on the clinical utility and influence on
decision-making of this test. Most studies have focused on
diagnostic performance; however, for a test to add
independent clinical value to the current diagnostic
standards (i.e. cystoscopy and cytology), it needs to
increase the discrimination of current tools integrating
established predictive characteristics that are used by
clinicians by a clinically and prognostically significant
margin [15]. In addition, its performance needs to be
tested for robustness according to clinical features to
make its applicability more generalizable [10]. Finally,
short of assessment in a biomarker-driven randomized
clinical trial, its true clinical benefit compared with the
current strategy needs to be tested in clinical decision
analysis [5]. We hypothesized that Bladder EpiCheck
would fulfil the three criteria needed in order to
recommend the integration of a biomarker into daily
clinical practice [16].
Materials and Methods
Study Design
This was a secondary analysis of a multicentre prospective
single-visit trial, assessing the prognostic performance of
Bladder EpiCheck as a non-invasive urine monitoring
test in patients with a history of NMIBC [14]. All patients
had a diagnosis of NMIBC <12 months before entering
the study; they underwent standard follow-up
investigations including cystoscopy and cytology according
to guideline recommendations [1] to exclude recurrent
disease.
Voided urine was collected prior to cystoscopy during the
follow-up to test the Bladder EpiCheck panel and cytology.
Patients and Endpoints
In the present secondary external independent analysis, we
investigated the performance of Bladder EpiCheck in the
detection of BCa, defined as positive cytology and/or
pathologically confirmed tumour on bladder biopsy.
Moreover, we sought to investigate the clinical utility of the
test and its differential impact on clinical decision-making
using multivariate analysis, changes in the area under the
curve (AUC) for prediction of recurrence, robustness in
subgroup analyses, and decision analytical methodology using
decision-curve analysis (DCA) [17].
Patients without Bladder EpiCheck results (n = 37), as well as
those with inconclusive cytology and/or cystoscopy findings
(n = 45), were excluded, leaving 357 patients for analysis
(Fig. S1). All data were provided to the authors and the
analyses and results were obtained without any restrictions by
industry.
Biomarker Analysis
Bladder EpiCheck is a urine assay based on 15 proprietary
methylation biomarkers. Methylation analyses were
performed as previously described [14]. Briefly, ≥10 mL of
urine is centrifuged. DNA is extracted from the obtained cell
pallet, digested using a methylation-sensitive restriction
enzyme which leaves methylated sequences intact, and
amplified by real-time PCR. Results are analysed with the
Bladder EpiCheck software.
A positive Bladder EpiCheck result was set at an EpiScoreTM
threshold of ≥60.
Statistical Analysis
Statistical analyses were performed in sequential steps [15].
First, sensitivity analysis was conducted to investigate the
performance of Bladder EpiCheck in the detection of any
and high-grade BCa. Second, the discrimination of Bladder
EpiCheck was plotted graphically using the receiver-
operating curve and assessed using the AUC. The 95% ‘bias-
corrected and accelerated’ confidence interval (95% CI) and
bias were computed via bootstrapping with 1000 replicates
Third, the association of Bladder EpiCheck with the
presence of BCa recurrence was tested in multivariate
analysis and adjusted for the effect of standard established
clinical characteristics. The generated coefficients were then
used to create two nomograms, one for the prediction of the
presence of any BCa and one for the prediction of high-
grade BCa. Internal validation was performed using 1000
bootstrap resamples. Calibration plots were generated to
assess the performance of the models. The additive
performance of Bladder EpiCheck was assessed by
comparing the discrimination of models with and without
Bladder EpiCheck. Fourth, the differential change in AUC
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attributed to Bladder EpiCheck was assessed in different
clinical subgroups to determine its robustness/
generalizability. Fifth, the clinical utility and the impact on
decision-making of Bladder EpiCheck was evaluated using
DCA. A post hoc power analysis was performed to estimate
the power of the model fitted. Finally, exploratory analysis
was conducted to investigate the effect of epidemiological
features on the performance of Bladder EpiCheck. P values
< 0.05 were taken to indicate statistical significance. All tests
were two-sided. Statistical analyses were performed using R
3.4.2 (R project, Vienna, Austria).
Results
A total of 357 patients were included in the analyses
(Fig. S1). The clinicopathological features of the included
patients are shown in Table 1. At the time of evaluation, 49
patients (13.7%) had experienced intravesical disease
recurrence. Overall, 70 (19.6%) had a positive Bladder
EpiCheck result. The test had a sensitivity of 67.3% (95%
CI 52–80) and a specificity of 88% (95% CI 84–91) for the
detection of any cancer (accuracy 85.2%, 95% CI 81–89;
Table 2), and a sensitivity of 88.9% (95% CI 65–99) and a
specificity of 88% (95% CI 84–91) for the detection of
high-grade cancer (accuracy 88.1%, 95% CI 84–91
[Table 2]).
In logistic regression analyses, a positive Bladder EpiCheck
result predicted the presence of any cancer with an odds ratio
(OR) of 15.1 (95% CI 7.71–30.77; P < 0.001) and the
presence of high-grade cancer with an OR of 58.6 (95% CI
15.8–380; P < 0.001 [Table 3]). As a continuous variable, an
increase in one Bladder EpiScore point corresponds to a 4%
increase in the risk of harbouring any BCa and an 8%
increase in the risk of harbouring a high-grade BCa (Table 3).
On multivariable logistic regression analysis that adjusted for
the effects of pathological stage, grade, age, gender, time from
last recurrence and ongoing intravesical therapy (base model)
Bladder EpiCheck remained independently associated with
the presence of any (OR 18.1, 95% CI 8.66–40.2; P < 0.001)
and high-grade BCa (OR 78.3, 95% CI 19.2–547; P < 0.001
[Tables 4 and 5]). Compared with the base model, the
addition of Bladder EpiCheck significantly improved the
prediction for any recurrence by 16% and high-grade
recurrence by 22% (AUC 85.9% and 96.1% for any and high-
grade cancer, respectively [Tables 4 and 5, Fig. S2]).
The clinical weight of Bladder EpiCheck in identifying any
and high-grade recurrence is depicted in nomograms that
were built using the coefficients of multivariable analyses
(Fig. 1). Internal validation, using the bootstrap method with
1000 resamples, showed that the model for the detection of
any BCa and that for the detection of high-grade BCa were
overfitted by 1.4% and 0.9%, respectively. Specifically, for the
detection of any BCa, the AUC for the model fitted to the
original data was 85.9% (95% CI 79.2–89.5). For the detection
of high-grade BCa, the AUC for the model fitted to the
original data was 96.1% (95% CI 90.9–97.9).
Calibration plots showed a good performance across
predicting probabilities (Fig. S3). Exploratory analyses showed
that the performance of the test, evaluated by the AUC, is not
affected by clinical features such as gender, age, smoking
status or occupational exposure (Figs S4 and S5).
The DCA showed that current predictors (i.e. last stage, last
grade) perform no better than cystoscopy in every patient (all
patients need cystoscopy), while the use of Bladder EpiCheck
Table 1 Clinicopathological features of 357 patients tested with Bladder
EpiCheck during the follow-up of non-muscle-invasive bladder cancer.
Overall
n 357
Age, median (IQR) 70.6 (63.5–78.4)
Women, n (%) 82 (23.0)
Occupational exposure, n (%)
No 192 (53.8)
Yes 41 (11.5)
Unknown 124 (34.7)
Smoking status, n (%)
Current 85 (23.8)
Former 203 (56.9)
Never 69 (19.3)
Years of smoking, median (IQR) 37 (25–48)
Pack-years, median (IQR) 33 (17–53)
Last pathological stage (%)
Ta 219 (61.3)
Tis 36 (10.1)
T1 97 (27.2)
NA 5 (1.4)
Last pathological grade (%)
Low grade 182 (51)
High grade 170 (47.6)
NA 5 (1.4)
Bladder EpiScore, median (IQR) 20 (13–32)
Positive Bladder EpiCheck, n (%) 70 (19.6)
Cytology, n (%)
Negative 324 (90.8)
Positive 22 (6.2)
Equivocal 11 (3.1)
Cystoscopy, n (%)
Negative 305 (85.4)
Positive 52 (14.6)
Pathology performed, n (%) 59 (16.5)
Pathology stage, n (%)
Ta 27 (7.6)
Cis 3 (0.8)
T0 21 (5.9)
T1 7 (2.0)
T2 1 (0.3)
Pathology grade, n (%)
High grade 18 (5.0)
Low grade 20 (5.6)
Adjuvant intravesical therapy, n (%)
BCG 72 (20.2)
MMC 111 (31.1)
Both 59 (16.5)
None 101 (28.3)
Other chemotherapy 14 (3.9)
Ongoing intravesical treatment at the time of testing (%) 102 (28.6)
IQR, interquartile range; MMC, mitomycin-C.
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for the purpose of deciding whether to perform a cystoscopy
or not during the follow-up of patients with a history of
NMIBC provided a net benefit relative to the current strategy
of evaluating all patients with cystoscopy, or that of testing
none of the patients (Fig. 2). This was true across threshold
probabilities between 10–60% for the presence of any BCa
and 5–55% for the presence of high-grade BCa, a range
within which all decisions based on standard predictors is
based in clinical practice. This translates into saving of
unnecessary cystoscopy and cytology in patients with a risk of
recurrence >10% for any BCa and >5% for high-grade BCa.
Decision-making based on Bladder EpiCheck could
significantly reduce the number of unnecessary cystoscopies
without missing any cancer as depicted in Tables 6 and 7 and
Fig. 3.
The post hoc power calculation showed that we had adequate
power to detect cancer recurrence. Specifically, with a sample
size of 352 patients and a multivariable logistic regression
model with seven degrees of freedom, we calculated a power
very close to 100%, with a 5% significance level to detect an
OR of 1.05 for Bladder EpiScore.
Table 2 Sensitivity analyses for the performance of Bladder EpiCheck in the detection of cancer in the follow-up of 357 patients with previous non-
muscle-invasive bladder cancer.
Any BCa High-grade BCa Low-grade BCa
Sensitivity, % (95% CI) 67 (52–80) 89 (65–99) 40 (19–64)
Specificity, % (95% CI) 88 (84–91) 88 (84–91) 88 (84–91)
PPV, % (95% CI) 47 (35–59) 30 (18–44) 18 (8–32)
NPV, % (95% CI) 94 (91–97) 99 (97–100) 96 (93–98)
Accuracy, % (95% CI) 85 (81–89) 88 (84–91) 85 (81–89)
Any BCa absent Any BCa present High-grade BCa
absent
High-grade BCa
present
Low-grade BCa absent Low-grade BCa present
Negative EpiCheck, n (%) 271 (75.9) 16 (4.5) 285 (79.8) 2 (0.6) 275 (77) 12 (3.4)
Positive EpiCheck, n (%) 37 (10.4) 33 (9.2) 54 (15.1) 16 (4.5) 62 (17.4) 8 (2.2)
BCa, bladder cancer; NPV, negative predictive value; PPV, positive predictive value.
Table 3 Univariable logistic regression analyses for the prediction of cancer based on the Bladder EpiCheck in the follow-up of 357 patients with
previous non-muscle-invasive bladder cancer.
Prediction of any BCa Prediction of high-grade BCa
OR 95% CI P OR 95% CI P
a) Positive Bladder EpiCheck result 15.1 7.71–30.77 <0.001 58.6 15.8–380 <0.001
b) Bladder EpiScore (continuous) 1.04 1.03–1.06 <0.001 1.08 1.05–1.12 <0.001
BCa, bladder cancer; OR, odds ratio.
Table 4 Multivariable regression analyses for the prediction of any cancer in the follow-up of 352 patients with previous non-muscle-invasive bladder
cancer.
Multivariable logistic regression analysis for positive Bladder EpiCheck Multivariable logistic regression analysis for continuous
Bladder EpiScore
OR 95% CI P OR 95% CI P
Last pathological stage (Ta reference category)
Tis 1.75 0.40–7.61 0.45 1.63 0.36–7.34 0.52
T1 1.36 0.43–4.36 0.60 1.47 0.46–4.76 0.52
High grade 0.74 0.25–2.09 0.58 0.68 0.23–1.91 0.47
Age (continuous) 0.99 0.96–1.03 0.84 0.99 0.95–1.02 0.56
Female gender 1.22 0.51–2.78 0.64 1.26 0.53–2.90 0.58
Time from last recurrence to urine collection 0.91 0.83–0.99 0.05 0.92 0.83–1.002 0.07
Ongoing intravesical therapy (never reference category)
No 1.24 0.56–2.86 0.60 1.20 0.53–2.79 0.65
Yes 0.27 0.08–0.84 0.03 0.29 0.08–0.91 0.04
AUC 66.9% (95% CI 58.1–70.7)
Positive EpiCheck 18.1 8.66–40.2 <0.001 EpiScore (continuous) 1.05 1.04–1.06 <0.001
AUC 85.1% (95% CI 78.2–88.9) AUC 85.9% (95% CI 79.2–89.5)
AUC, area under the curve; OR, odds ratio.
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Discussion
In this secondary independent analysis of the Bladder
EpiCheck study [14], we confirmed the high diagnostic
accuracy and performance of the Bladder EpiCheck test.
NMIBC is one of the most expensive cancers per patient,
largely because of its high rate of recurrences, necessitating
intense surveillance [2]. Lowering the number of
cystoscopies would reduce the cost of surveillance and
simultaneously improve patients’ quality of life. In this
clinical setting, we need a test with high negative predictive
value (NPV) for all BCa but specifically for high-grade BCa,
which is the most important not to miss as it could lead to
stage progression. Indeed, NPV is to be considered a point
of reference from which measurements may be made in
order to avoid unnecessary intervention, thereby improving
patients’ quality of life. By contrast, positive predictive value
has more value in a screening setting where early detection
is essential; however, the influence of disease prevalence on
predictive values must be taken into account in the BCa
population for biomarker discovery, design and validation
[15].
In accordance with the first report of the trial, we found that
Bladder EpiCheck could exclude the presence of high-grade
BCa with an NPV of 99.3%, that is a false-negative result of
0.7 per 100 patients with negative results. This provides
Table 5 Multivariable regression analyses for the prediction of high-grade cancer in the follow-up of 321 patients with previous non-muscle-invasive
bladder cancer.
Multivariable logistic regression analysis for positive Bladder EpiCheck Multivariable logistic regression analysis for continuous
Bladder EpiScore
OR 95% CI P OR 95% CI P
Last pathological stage (Ta reference category)
Tis 3.96 0.42–40.7 0.23 5.44 0.49–69.0 0.99
T1 3.43 0.63–23.1 0.17 5.62 0.88–46.9 0.17
High grade 1.00 0.18–4.97 0.99 0.64 0.09–3.54 0.08
Age (continuous) 0.98 0.93–1.05 0.63 0.97 0.91–1.04 0.62
Female gender 0.77 0.14–3.26 0.73 0.93 0.16–4.36 0.39
Time from last recurrence to urine collection 0.82 0.66–0.96 0.03 0.82 0.65–0.99 0.93
Ongoing intravesical therapy (never reference category)
No 0.95 0.22–4.09 0.94 0.82 0.06–2.33 0.81
Yes 0.40 0.06–2.07 0.29 0.40 0.06–2.33 0.32
AUC 72.7% (95% CI 62.7–76.6)
Positive EpiCheck 78.3 19.2–547 <0.001 EpiScore (continuous) 1.08 1.05–1.12 <0.001
AUC 94.9% (95% CI 88.3–96.8) AUC 96.1% (95% CI 90.9–97.9)
AUC, area under the curve; OR, odds ratio.
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Fig. 1 Logistic regression nomogram for the prediction of bladder cancer (BCa) (A) and high-risk BCa (B) in the follow-up of patients with previous non-
muscle invasive bladder cancer. CIS, carcinoma in situ; LG, low grade; HG, high grade; PUNLMP, papillary urothelial neoplasm of low malignant
potential.
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physicians and patients with a very high certainty that no
tumour recurrence is present if the test is negative, largely
outperforming the currently available urinary-based
biomarkers and cystoscopy. For example, in recent studies
evaluating blue-light cystoscopy in the surveillance setting, the
sensitivity and specificity of white-light cystoscopy were
79.3% and 78%, respectively [18]. Moreover, the overall
sensitivity and specificity for urine-based biomarkers, such as
NMP22, reached only 73% and 80%, respectively [19]. Similar
results can be observed for other commercially available tests,
such as ImmunoCytTM and UroVysionTM [20]. Owing to poor
study design, resulting in a wide range of performances and a
sensitivity that is usually relatively high at the cost of lower
specificity, none of these urinary tests is recommended in the
surveillance of NMIBC by current guidelines [1]. Bladder
EpiCheck achieved a sensitivity of 89% and a specificity of
88% for high-grade BCa.
Urine cytology, the only established urine-based ‘marker’ used
in routine clinical practice for the diagnosis and surveillance
of BCa is limited by suboptimal NPV, specifically for low-
grade cancer, and does not comply fully with the
requirements set forth for an ideal biomarker [16]. As the
association of Bladder EpiCheck with positive urine cytology
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Fig. 2 Decision-curve analysis assessing the clinical impact of the nomograms estimating the prediction of bladder cancer (BCa) (A) and high-risk BCa
(B) in the follow-up of patients with previous non-muscle-invasive BCa. The inclusion of EpiScore is compared with current clinical prognostic models
and the strategies of evaluating all or none of the patients with cystoscopy and cytology.
Table 6 Net benefits and interventions avoided for the models assessed through decision-curve analysis for the detection of any cancer in the follow-up
of 352 patients with non-muscle-invasive bladder cancer.
Threshold
probability (%)
Net benefits Interventions avoided per 100 patients
Treat all Treat none Treat based on
Bladder EpiScore
Treat based on
current predictors
Advantage Bladder EpiScore Current predictors
5 0.09 0 0.09 0.089 0.001 2.6 0
10 0.04 0 0.08 0.05 0.03 35.2 3.98
15 0.01 0 0.07 0.003 0.067 49.5 8.8
20 0.08 0 0.07 0 0.14 57.1 30.4
25 0.01 0 0.06 0 0.21 61.9 44.3
30 0.02 0 0.05 0 0.28 65.2 53.6
35 0.03 0 0.04 0 0.37 68.3 60.2
40 0.04 0 0.04 0 0.47 71 65.2
45 0.06 0 0.03 0 0.59 72 69.1
50 0.07 0 0.03 0 0.75 75 72.1
55 0.09 0 0.02 0 0.93 76.5 74.7
60 1.1 0 0.01 0 1.16 77.6 76.8
65 1.5 0 0 0 1.46 78.6 78.6
70 1.9 0 0 0 1.87 80 80
In decision-curve analysis prediction models are compared to two default strategies: (i) assume that all patients are test positive and therefore treat everyone, or (ii) assume that all
patients are test negative and offer treatment to no one. The table shows the net benefits for a strategy of performing a cystoscopy in every patient (treat all), in no one (treat none),
based on Bladder EpiCheck and on current predictors (i.e. last stage and last grade). For example, given a personal threshold probability of 15% (i.e. one would undergo a
cystoscopy if the probability of cancer is >15%) the value of 0.07 can be interpreted as: ‘Compared to performing no cystoscopy, performing a cystoscopy on the basis of the Bladder
EpiCheck is the equivalent of a strategy that found seven cancers per 100 patients without conducting any unnecessary cystoscopy’. Moreover, at this threshold probability every
decision based on Bladder EpiCheck would avoid 49.5% of unnecessary cystoscopies without missing any cancer.
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was an endpoint in the present analysis, a direct comparison
of the performance of these two tests was not possible. We
chose positive cytology as an endpoint because white-light
cystoscopy has a significant false-negative rate and cytology a
high true-positive rate [1]. Nevertheless, considering only the
accuracy for low-grade BCa, Bladder EpiCheck largely
outperformed cytology, which in the present cohort was 20%
in agreement with the reported literature [1,4]. While the
diagnostic performance of a test is important, its association
with the outcome of interest should be independent of
established clinicopathological features [15] and it should
further add prognostically and clinically independent
information to what we already know.
We found that Bladder EpiCheck was independently
associated with the presence of BCa in multivariable analysis
and its diagnostic AUC performance was robust within
subgroups. Specifically, the results of Bladder EpiCheck were
independent of previous or ongoing intravesical therapy.
This represents a great advantage compared with other
available urine biomarkers, whose performance varies with
different clinical features [21] or which have high variability
in performance depending on the selected threshold [22].
Indeed, Bladder EpiCheck reached an AUC of 83% for the
prediction of any cancer and 95% for the prediction of high-
grade cancer in multivariable analysis, significantly
improving the AUC of a prediction model which included
Table 7 Net benefits and interventions avoided for the models assessed through decision-curve analysis for the detection of high-grade cancer in the
follow-up of 321 patients with non-muscle-invasive bladder cancer.
Threshold
probability (%)
Net benefit Interventions avoided per 100
patients
Treat all Treat none Bladder EpiScore Current
predictors
Advantage Bladder
EpiScore
Current predictors
5 0.006 0 0.04 0.013 0.04 70.7 13.4
10 0.05 0 0.04 0 0.09 77.6 44
15 0.11 0 0.03 0 0.14 80.6 63
20 0.18 0 0.03 0 0.21 83.5 72
25 0.26 0 0.03 0 0.28 85.7 77.6
30 0.35 0 0.02 0 0.37 85.6 81.3
35 0.45 0 0.02 0 0.47 87.5 84
40 0.57 0 0.02 0 0.59 88.9 86
45 0.72 0 0.012 0 0.73 89 87.5
50 0.89 0 0.006 0 0.89 89.4 88.8
55 1.1 0 0.003 0 1.1 90 89.8
60 1.36 0 0 0 1.36 90.6 91
65 1.7 0 0 0 1.7 91.4 92
70 2.15 0 0 0 2.15 92 92
In decision-curve analysis prediction models are compared to two default strategies: (i) assume that all patients are test positive and therefore treat everyone, or (ii) assume that all
patients are test negative and offer treatment to no one. The table shows the net benefits for a strategy of performing a cystoscopy in every patient (treat all), in no one (treat none),
based on Bladder EpiCheck and on current predictors (i.e. last stage and last grade). For example, given a personal threshold probability of 5% (i.e. a patient would undergo a
cystoscopy if the probability of high-grade cancer is >5%) the value of 0.04 can be interpreted as: ‘Compared to performing no cystoscopy, performing a cystoscopy on the basis of
the Bladder EpiCheck is the equivalent of a strategy that found four cancers per 100 patients without conducting any unnecessary cystoscopy.’ Moreover, at this threshold probability
every decision based on Bladder EpiCheck would avoid 70.7% of unnecessary cystoscopies without missing any cancer.
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Fig. 3 Interventions avoided by the use of Bladder EpiCheck in the decision-making of evaluating a patient with cystoscopy and cytology during the
follow-up of non-muscle-invasive bladder cancer (BCa), based on the risk of having any BCa (A) or high-risk BCa (B) recurrence.
© 2019 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International 965
Clnical utility of the Bladder EpiCheck test
pathological stage, grade, age, gender, time from last
recurrence and ongoing intravesical therapy by 16% and
22%, respectively. However, achieving independent
association on multivariable testing and improvement in
AUC does not directly translate into clinical utility, making
decision analyses critical.
On DCA, we found that Bladder EpiCheck could provide a
significant clinical benefit by reducing the number of
unnecessary cystoscopies without missing any cancer during
the follow-up of patients with NMIBC. Current guidelines
suggest standardized follow-up of patients with NMIBC [1],
but the invasiveness of the procedure and the intervals often
result in patient anxiety, organizational challenges and
deviation from recommended standards [23,24]. Biomarkers
in surveillance could help reduce the number of unnecessary
cystoscopies, thereby reducing the economic burden,
improving patient’s quality of life and, ultimately, allowing
individualization of follow-up and therapy [10,15,16].
Several studies have proposed replacing or alternating
follow-up cystoscopies with urinary biomarkers, but none of
the tests to date could reach sufficient diagnostic accuracy to
reliably replace cystoscopy as the reference standard
[5,8,10,15,16,25]. A recent up-to-date catalogue summarizes
the performance of panels as well as single urinary
biomarkers in the surveillance of NMIBC [26]. None of
these tests achieved a diagnostic accuracy comparable to the
Bladder EpiCheck. Moreover, the Bladder EpiCheck
demonstrated a robust performance and significant impact
on clinical decision-making and, based on current data,
could therefore be implemented in clinical practice to decide
whether to perform a cystoscopy or not. For example, given
a personal threshold probability of 15% (i.e. a patient would
undergo a cystoscopy if the probability of cancer was >15%)
every decision based on Bladder EpiCheck would avoid
49.5% of unnecessary cystoscopies without missing any
cancer.
Limitations of the present study are those inherent to its
single-visit design, similar to most diagnostic biomarker
studies. Because a negative test does not exclude future
recurrences, future studies should focus on longitudinal
assessment of changes in the Bladder EpiScore as these
may give insight into the risk of development of urothelial
cancer in patients with subclinical disease [27]. Indeed, a
movement toward risk-based counselling and decision-
making holds the promise of personalizing medicine in a
highly heterogeneous, complex clinical entity such as
NMIBC.
In conclusion, the Bladder EpiCheck test offers a highly
promising diagnostic performance in ruling out BCa
recurrence and has relevant clinical consequences as it could
reduce the number of unnecessary investigations, thereby
reducing costs per patient, improving patients’ quality of life
and providing safe follow-up of patients with NMIBC.
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